

Section 1: Identification

Product Name	Testosterone USP Micronized CIII (Yam)
Commercial Name	Not available.
Product Use	Not available.
Restrictions On Use	Not available.
Product Code	23-4324
Company	PCCA 9901 South Wilcrest Houston, TX 77099 Phone: 1-800-331-2498 Fax: 1-800-874-5760
	In case of emergency contact: CHEMTREC (24hr) 1-800-424-9300

Section 2: Hazard(s) Identification

OSHA Haz Com:	Acute toxicity, oral (Category 4) Carcinogenicity (Category 1B) Reproductive toxicity (Category 1)
CFR 1910.1200	
Signal Word	DANGER
Hazard Statement(s)	Harmful if swallowed. May cause cancer. Suspected of damaging fertility or the unborn child. Very toxic to aquatic life.

Pictogram(s) or Symbol(s)

Precautionary Statement(s):

Prevention	Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection.
Response	If swallowed: Call a poison center/doctor if you feel unwell. Rinse mouth. If exposed or concerned: Get medical advice/attention.
Storage	Store locked up
Disposal	Dispose of contents/container in accordance with local/regional/national/international regulations

Section 3: Composition/Information on Ingredients

Substance/Mixture	Substance
Components	Testosterone USP Micronized
% By Weight	100
CAS#	58-22-0
Molecular Weight	288.41 g/mole
Chemical Formula	C19-H28-O2
Synonym(s)	17beta-Hydroxy-androst-4-en-3-one; Testosterone USP Micronized 17b-hydroxy-4-androstene-3-one

Mixtures	Name	CAS#	% by Weight	TLV/PEL	LC50/LD50
	Testosterone	58-22-0	100		

Section 4: First-Aid Measures

Inhalation	Move to fresh air. If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing. Call a physician if symptoms develop or persist.
Skin Contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye Contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately.
Symptoms/Effects	
Acute	Potent pharmacologically active material. Occupational exposure to small amounts may cause physiological effects.
Delayed	Potent pharmacologically active material. Occupational exposure to small amounts may cause physiological effects.

Immediate Medical Attention

Provide general supportive measures and treat symptomatically. Monitor vital signs. Monitor ECG. Monitor liver function. Gastrointestinal decontamination is generally not necessary. Dialysis will not effectively remove this material. Urinary alkalinization is NOT recommended.

Section 5: Fire-Fighting Measures**Suitable Extinguishing Media**

Water. Foam. Dry chemical or CO₂. Use fire-extinguishing media appropriate for surrounding materials.

Unsuitable Extinguishing Media

Not available.

Products of Combustion

No unusual fire or explosion hazards noted.

Firefighters Special Equipment and Precautions

Wear suitable protective equipment. Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

Section 6: Accidental Release Measures**Section 7: Handling and Storage**

Handling: As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Select and use containment devices and personal protective equipment based on a risk assessment of material potency and exposure potential. **Storage:** Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

Section 8: Exposure Controls/Personal Protection

Exposure Limits	TWA 0.9 micrograms/m ³ T
Engineering Controls	No open handling. For laboratory operations, use approved ventilation or containment system (biological safety cabinet, ventilated balance enclosure, glovebox). Control exposures to below the occupational exposure level (if available). Select and use containment devices and personal protective equipment based on a risk assessment of exposure potential. Cover all containers for solutions and slurries while being transferred.



Safety Data Sheet

For Compliance with OSHA 29 CFR 1910.1200 and ANSI Z400.1-1998

Personal Protection

Eye/face protection: Wear safety glasses with side shields, chemical splash goggles, or full face shield, if necessary. Base the choice of protection on the job activity and potential for contact with eyes or face. An emergency eye wash station should be available. Skin protection Hand protection: Consider double gloves. Wear nitrile or other impervious gloves if skin contact is possible. When the material is dissolved or suspended in an organic solvent, wear gloves that provide protection against the solvent. Other: Train employees in proper gowning and degowning practices. Wear disposable lab coat, disposable sleeve covers and two pair of gloves as appropriate for the task. Base the choice of skin protection on the job activity, potential for skin contact and solvents and reagents in use. Do not wear protective garments in common areas (e.g., cafeterias) or out-of-doors. Respiratory protection: Use a powered air-purifying respirator (PAPR) with HEPA filters, disposable outerware and head cover for spill cleanup. Choose respiratory protection appropriate to the task and the level of existing engineering controls. Thermal hazards: Wear appropriate thermal protective clothing, when necessary. General hygiene considerations: Pharmacological effects may be seen with occupational exposure. Handling practices in this SDS are recommendations for laboratory use of reference standards. Procedures for any other uses or quantities should be determined after an appropriate assessment.

Section 9: Physical and Chemical Properties

Appearance	White. Cream. Powder. solid.		
Odor	Odorless.		
Odor Threshold	Not available.		
Melting Point	307.4 - 314.6 °F (153 - 157 °	pH	Not available.
Freezing Point	Not available.	Vapor Pressure	< 0.0000001 kPa at 25 °C
Boiling Point/Range	Not available.	Vapor Density	Not available.
Decomposition temperature	Not available.	Viscosity	Not available.
Partition Coefficient: n-octanol/water	3.32	Evaporation Rate	Not available.
Flash Point	Not available.	Autoignition temperature	Not available.
Flammability	Not available.	Flammability or Explosive Limits:	
		Lower	Not available.
		Upper	Not available.
Solubility(ies)	Practically insoluble in water.		
Other	Chloroform: Freely soluble. Dehydrated alcohol: Freely soluble. Dioxane: Soluble. Ether: Slightly soluble. Chemical family Anabolic steroid. Molecular formula C19H28O2 Molecular weight 288.42		

Section 10: Stability and Reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical Stability	Material is stable under normal conditions.
Hazardous Polymerization	No dangerous reaction known under conditions of normal use.
Conditions to Avoid	Contact with incompatible materials.
Incompatible Materials	Strong oxidizing agents.
Hazardous Decomposition Products	Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

Section 11: Toxicological Information

RTECS	XA3030000
Acute Toxicity	
Oral: LD50 > 5000 mg/kg (mammals) Acute Dermal: LD50 Rat > 2000 mg/kg, 24 Hours Acute Oral: LD50 Rat 500 - 1000 mg/kg	
Skin Corrosion/Irritation	
Not available.	
Serious Eye Damage/Irritation	
Not available.	
Respiratory or Skin Sensitization	
Not available.	
Germ Cell Mutagenicity	
Not available.	
Carcinogenicity	
May cause cancer. Hepatocellular carcinomas and hepatic neoplasms have been associated rarely with long-term, high-dose anabolic steroid therapy.	
Reproductive Toxicity	

May damage fertility or the unborn child. Studies in humans have shown that androgens administered during pregnancy cause masculinization of the external genitalia of the female fetus; the degree of masculinization is dose related. In males, absent, low, or reduced sperm or sperm function resulting in possible infertility may occur during high-dose therapy with androgens. In females treated with androgens, the absence of menstruation may result, impairing fertility. Anabolic steroid use during pregnancy may cause premature bone maturation and decreased birthweight in the fetus

Routes of Entry

Ingestion.

Symptoms Related to Exposure

Anabolic steroids: Reproductive effects. Gastrointestinal disturbances. Weight gain. Swelling of feet and legs. Behavior, mood or mental changes. Liver toxicity. Water and sodium retention. Impaired glucose tolerance. Cancer.

Potential Health Effects

Not available.

Target Organ(s) Not available.

Section 12: Ecological Information**Ecotoxicity**

The product is not classified as environmentally hazardous. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment

Persistence and Degradability

Not available.

Bioaccumulative Potential

log Kow 3.32

Mobility in Soil

Not available.

Other Adverse Effects

Not available.

Section 13: Disposal Considerations**Waste Disposal**

Under RCRA, it is the responsibility of the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste.

Disposal of Container

Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner

Other Considerations

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

Section 14: Transport Information**DOT Classification**

Not a DOT controlled material (United States). This material is not classified dangerous good according to international transportation regulations (ADR/RID-IMDG-ICAO/IATA).

Section 15: Regulatory Information**Regulations**



Safety Data Sheet

For Compliance with OSHA 29 CFR 1910.1200 and ANSI Z400.1-1998

California prop. 65: This product contains the following ingredients for which the State of California has found to cause cancer, birth defects or other reproductive harm, which would require a warning under the statute: Testosterone California prop. 65: This product contains the following ingredients for which the State of California has found to cause reproductive harm (female) which would require a warning under the statute: Testosterone California prop. 65: This product contains the following ingredients for which the State of California has found to cause reproductive harm (male) which would require a warning under the statute: Testosterone California prop. 65: This product contains the following ingredients for which the State of California has found to cause cancer which would require a warning under the statute: Testosterone Pennsylvania RTK: Testosterone Florida: Testosterone Massachusetts RTK: Testosterone New Jersey: Testosterone California Director's List of Hazardous Substances: Testosterone TSCA 8(b) inventory: Testosterone

Other

WHMIS (Canada): Not controlled under WHMIS (Canada).

Section 16: Other Information

Not available.